Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
NIH BRAIN Initiative Director John Ngai and Acting NINDS Director Amy Bany Adams jointly announced the formal publication of the BRAIN Initiative's 10-year Neuroscience Research Roadmap on 15 May 2026, with a Director's Message and a paper in Neuron. The roadmap, finalised in August 2025, organises the next decade of US federally-funded neuroscience around four Innovation Domains: BRAIN Knowledgebase, Precision Molecular Circuit Therapies, Accelerating Human Neuroscience, and BRAIN NeuroAI.
Neuralink disclosed on 7 May 2026 that its next-generation R1 surgical robot can place electrode threads into virtually any region of the human brain, threading through the dura mater with real-time motion compensation and a suite of eight optical coherence tomography cameras. The scope expansion opens Parkinson's disease, refractory epilepsy, and treatment-resistant depression as new target indications beyond motor-function restoration.
Neurosoft Bioelectronics closed a $7.5 million oversubscribed seed round on 20 May 2026, led by Skybound Venture Capital and joined by PL Capital, IAG Capital Partners, and Connecticut Innovations. The round brings Neurosoft's total funding past $20 million and is the inaugural investment from Skybound, a new Athens-based deeptech fund publicly launched the same week with a $38 million first close anchored by the European Investment Fund.
Medtronic announced on 20 May 2026 its intent to acquire SPR Therapeutics, the maker of the Sprint percutaneous peripheral nerve stimulation system, for approximately $650 million in upfront cash. The deal is the second top-three neuromodulation acquisition of a PNS specialist in seven months, after Boston Scientific completed its $533 million purchase of Nalu Medical in January 2026.
Governor Phil Scott signed H.814 into law on 18 May 2026, making Vermont the fifth US state with neural data privacy legislation on the books after Colorado, California, Montana, and Connecticut. The enacted text is the 6-page version of a bill that originally cleared the House at 32 pages; the consent requirement and private right of action did not survive the Senate amendment process. Effective 1 July 2026.
Mobia Medical, the company behind the only FDA-approved implanted vagus nerve stimulator for chronic stroke recovery, priced its $150 million IPO at $15 on 7 May 2026 and closed week one at $11.75. The print resets implied exit math for the pre-IPO bioelectronic-medicine cohort preparing 2026-27 listings.
BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.
Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.